Ergoplex, an anti-inflammatory product, receives good response in direct mail test

OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that Ergoplex™, its commercial anti-inflammatory product using its patented compound, Ergothioneine, a powerful antioxidant, has shown very good acceptance in a recent direct mail test. Response rates ranged from 1.6% to 2.2%; levels indicative of broad consumer acceptance.

Tony Cataldo, Chairman and CEO of Oxis, stated, “The results of the recent direct mail test are extremely exciting and we believe this data supports our contention that Ergoplex will be a successful product in the fight against oxidative stress and inflammation. These tests are the first steps towards a full launch of Ergoplex as our first commercial product. We expect to announce additional products in our pipeline as we continue to develop our portfolio.”


OXIS International, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The influence of COVID-19 on platelet activation and aggregation